Loading clinical trials...
Loading clinical trials...
A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the BB305 Lentiviral Vector in Subjects With Sickle Cell Disease
Conditions
Interventions
bb1111
Locations
9
United States
University of Alabama
Birmingham, Alabama, United States
Children's National Hospital
Washington D.C., District of Columbia, United States
Tufts Medical Center
Boston, Massachusetts, United States
University of Minnesota
Minneapolis, Minnesota, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Montefiore Medical Center
The Bronx, New York, United States
Start Date
February 14, 2020
Primary Completion Date
May 1, 2027
Completion Date
November 1, 2027
Last Updated
December 10, 2024
NCT06612268
NCT06820515
NCT07392216
NCT07187973
NCT04416178
NCT05359991
Lead Sponsor
Genetix Biotherapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions